Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese. Local targets link to admitted publications; unresolved targets remain external evidence.
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
2022 · External reference
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
10.1002/hep.29367 · 2018 · External reference
10.1002/hep.23594
10.1002/hep.23594 · External reference
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
10.3748/wjg.v20.i2.475 · 2014 · External reference
10.1146/annurev-pathol-020117-043617
10.1146/annurev-pathol-020117-043617 · External reference
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
10.1016/j.jhep.2020.03.039 · 2020 · External reference
A multi-society Delphi consensus statement on new fatty liver disease nomenclature
2023 · External reference
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature reviews Gastroenterology &
2021 · External reference
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
10.1097/hep.0000000000000542 · 2024 · External reference
Metabolomics discloses a new non-invasive method for the diagnosis and prognosis of patients with alcoholic hepatitis
10.5604/01.3001.0012.7906 · 2019 · External reference
Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts
10.1002/hep4.1188 · 2018 · External reference
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis
10.1016/j.jhep.2021.04.013 · 2021 · External reference
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
10.1097/mcg.0b013e3181dd1348 · 2011 · External reference
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
10.1002/hep.27173 · 2014 · External reference
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
10.1002/hep4.1188 · 2018 · External reference
The use of BMI and waist circumference as surrogates of body fat differs by ethnicity
10.1038/oby.2007.334 · 2007 · External reference
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease
10.1002/hep.22350 · 2008 · External reference
10.1016/j.jhep.2021.09.024
10.1016/j.jhep.2021.09.024 · External reference
Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis
10.1002/oby.22627 · 2019 · External reference
PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer
10.1159/000282095 · 2010 · External reference
Omega-3 fatty acids and metabolic partitioning of fatty acids within the liver in the context of nonalcoholic fatty liver disease
2022 · External reference
10.1016/j.freeradbiomed.2020.02.025
10.1016/j.freeradbiomed.2020.02.025 · External reference
Elevated citrate levels in non-alcoholic fatty liver disease: the potential of citrate to promote radical production
10.1016/j.febslet.2013.06.019 · 2013 · External reference
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
10.1002/hep.25630 · 2012 · External reference
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
10.1002/hep.29465 · 2018 · External reference
Branched chain amino acids: Passive biomarkers or the key to the pathogenesis of cardiometabolic diseases?
10.17219/acem/104542 · 2019 · External reference
N-Acyl taurines trigger insulin secretion by increasing calcium flux in pancreatic beta-cells
10.1016/j.bbrc.2012.11.026 · 2013 · External reference
Metabolomics analysis identifies different metabotypes of asthma severity
10.1183/13993003.01740-2016 · 2017 · External reference
Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84
10.1172/jci.insight.165469 · 2023 · External reference
Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease
10.1053/j.gastro.2013.11.049 · 2014 · External reference
The plasma lipidomic signature of nonalcoholic steatohepatitis
10.1002/hep.23229 · 2009 · External reference
Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice
10.1002/hep.29039 · 2017 · External reference
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
10.1007/s00125-013-2981-2 · 2013 · External reference
Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
2017 · External reference
